The U.S. Food and Drug Administration (FDA) has approved a new version of the drug Ingrezza, called Ingrezza Sprinkle. This medication is used to treat adults with two specific movement disorders. The first is tardive dyskinesia, which causes uncontrollable movements of the face and body, often as a side effect of certain mental health medicines. The second is chorea, the jerky, dance-like movements associated with Huntington's disease.
This new 'sprinkle' form is designed to be easier to take. The capsule can be opened, and the contents can be sprinkled onto soft foods like applesauce or pudding. This can be helpful for people who have trouble swallowing pills. The drug itself works in the brain to help reduce these involuntary movements.
The approval means that doctors and patients now have another choice for managing these often challenging conditions. It is based on studies of the original Ingrezza capsule, which showed it was effective. The main new feature is this different way of taking the medicine, which may help some people stick with their treatment plan more easily.
It is important to note that this approval does not include separate clinical trial results for the sprinkle form itself. As with any new medication option, patients should have a conversation with their doctor to understand if Ingrezza Sprinkle is a suitable choice for their individual health situation.
